Physician

Anne M Favret, M.D.

According to 2025 Medicare claims, Anne Favret, M.D. (NPI: 1205803202) practices hematology/oncology in the Arlington-Alexandria-Reston, VA-WV market, with the plurality of this provider's patient population coming from Fairfax, VA. This provider's primary affiliated billing organization is VIRGINIA CANCER SPECIALISTS, P.C. (NPI: 1346294519; TIN: 541795091) and primary practice location at 22031-2172.

Favret's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,051 traditional Medicare patients, billed 104,999 HCPCS/CPT codes, and received $1,500,222 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,035 prescription claims across 300 beneficiaries totaling $1,857,454 in drug costs, led by Ibrance (Palbociclib). 2023 DME data shows 25 claims. Open Payments data shows 364 records totaling $979,606. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $874,972 and ending at $1,500,222. Concurrently, Part D prescription costs have risen steadily, from $240,249 to $1,857,454. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,721	58,047	$874,972
2016	1,792	58,348	$951,635
2017	2,124	72,267	$1,270,769
2018	1,970	64,975	$1,222,215
2019	2,407	126,129	$2,126,316
2020	2,381	131,175	$1,909,265
2021	1,471	67,162	$1,237,468
2022	1,130	89,064	$1,636,249
2023	1,106	95,187	$1,655,478
2024	1,051	104,999	$1,500,222

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	184	676	$240,249
2016	226	803	$334,794
2017	247	912	$479,078
2018	234	906	$736,197
2019	234	762	$396,452
2020	225	767	$705,800
2021	243	784	$842,041
2022	231	768	$574,521
2023	262	893	$1,116,853
2024	300	1,035	$1,857,454

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	84	$29,713
2017	N/R	86	$20,816
2018	N/R	32	$5,142
2019	N/R	44	$3,533
2020	N/R	57	$3,469
2021	N/R	16	$661
2022	N/R	N/R	N/R
2023	N/R	25	$4,083
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	295	455	$103
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	279	330	$72
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	267	352	$14
80053	Blood test, comprehensive group of blood chemicals	357	882	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	192	670	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	92	2,576	$1,480,471
Brukinsa	Zanubrutinib	11	330	$171,758
Exemestane	Exemestane	92	7,187	$11,806
Anastrozole	Anastrozole	599	47,004	$11,700
Letrozole	Letrozole	117	9,330	$3,000

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$41	Daiichi Sankyo Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	362	$979,565	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Anne M. Favret, M.D.?

Tedicare shows public-source Medicare data for Anne M. Favret, M.D. (NPI 1205803202), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Anne M. Favret, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Anne M. Favret, M.D.?

Anne M. Favret, M.D. is linked to VIRGINIA CANCER SPECIALISTS, P.C. (billing NPI 1346294519) in the available physician profile data.

Does Anne M. Favret, M.D. have Open Payments data?

Anne M. Favret, M.D. has 364 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.